Literature DB >> 26903183

The eye and the skin in endocrine metabolic diseases.

Julio A Urrets-Zavalía1, Evangelina Espósito2, Iliana Garay3, Rodolfo Monti2, Alejandro Ruiz-Lascano3, Leandro Correa2, Horacio M Serra4, Andrzej Grzybowski5.   

Abstract

The eye and skin may offer critical clues to the diagnosis of a varied spectrum of metabolic diseases from endocrine origin and their different stages of severity, such as diabetes mellitus and Graves disease. On the other hand, such entities may compromise the eye and visual function severely, and awareness of these possible associations is an important step in their diagnosis and management. A large number of less common endocrine diseases may also have significant ocular/visual or skin involvement. Often the etiologic relationship between the endocrine metabolic disease and the ocular compromise is unknown, but diverse pathogenetic mechanisms may act through a common pathologic pathway producing ocular damage, as occur in diabetic retinopathy. This review emphasizes the ocular and skin manifestations of different metabolic diseases of endocrine origin.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26903183     DOI: 10.1016/j.clindermatol.2015.12.001

Source DB:  PubMed          Journal:  Clin Dermatol        ISSN: 0738-081X            Impact factor:   3.541


  3 in total

Review 1.  Ophthalmic manifestations of endocrine disorders-endocrinology and the eye.

Authors:  Alisha Kamboj; Michael Lause; Priyanka Kumar
Journal:  Transl Pediatr       Date:  2017-10

2.  [Pretibial myxoedema in Graves' disease].

Authors:  Alejandra Tomás-Velázquez; Pablo Panadero Meseguer; Leyre Aguado
Journal:  Aten Primaria       Date:  2019-03-04       Impact factor: 1.137

3.  Clinical, histological and genetic findings in a donor with a clinical history of type 1 Autoimmune Polyendocrinopathy Syndrome.

Authors:  Catherine J Culp; Christian M Pappas; Marc Toso; Phillip Qu; Nick Mamalis; Gregory S Hageman
Journal:  Am J Ophthalmol Case Rep       Date:  2022-01-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.